Epitope mapping of antibodies induced with a conserved rhinovirus protein generating protective anti-rhinovirus immunity

File Description SizeFormat 
Narean et al manuscript revision.docxFile embargoed until 16 April 2020115.82 kBMicrosoft Word    Request a copy
Narean et al Fig..pdfFile embargoed until 16 April 20202.14 MBAdobe PDF    Request a copy
Title: Epitope mapping of antibodies induced with a conserved rhinovirus protein generating protective anti-rhinovirus immunity
Authors: Narean, JS
Glanville, N
Nunn, CM
Niespodziana, K
Valenta, R
Johnston, SL
McLean, GR
Item Type: Journal Article
Abstract: Human rhinovirus (RV) infections are the principle cause of common colds and precipitate asthma and chronic obstructive pulmonary disease (COPD) exacerbations. Currently there is no vaccine for RV which is largely due to the existence of ∼160 serotypes/strains. We demonstrated previously that immunising mice with highly conserved VP4 and VP2 regions of the RV polyprotein (RV-A16 VP0) generated cross-reactive immunity to RV in vivo. The current study investigated and mapped the epitopes of RV-A16 VP0 that are targets for antibodies in serum samples from VP0 immunisation and RV challenge studies in mice. Recombinant capsid proteins, peptide pools and individual peptides spanning the immunogen sequence (RV-A16 VP0) were assessed for IgG binding sites to identify epitopes. We found that peptide pools covering the C-terminus of VP4, the N-terminus of VP2 and the neutralising NIm-II site within VP2 were bound by serum IgG from immunised mice. The NIm-II site peptide pool blocked IgG binding to the immunogen RV-A16 VP0 and individual peptides within the pool binding IgG were further mapped. Thus, we have identified immunodominant epitopes of RV vaccine candidate RV-A16 VP0, noting that strong IgG binding antibodies were observed that target a key neutralising epitope that is highly variable amongst RV serotypes.
Issue Date: 9-May-2019
Date of Acceptance: 9-Apr-2019
URI: http://hdl.handle.net/10044/1/71661
DOI: https://doi.org/10.1016/j.vaccine.2019.04.018
ISSN: 0264-410X
Publisher: Elsevier
Start Page: 2805
End Page: 2813
Journal / Book Title: Vaccine
Volume: 37
Issue: 21
Copyright Statement: © 2019 Elsevier Ltd. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence http://creativecommons.org/licenses/by-nc-nd/4.0/.
Sponsor/Funder: Commission of the European Communities
Asthma UK
Commission of the European Communities
Funder's Grant Number: 233015
Asthma UK Centre
260895
Keywords: Science & Technology
Life Sciences & Biomedicine
Immunology
Medicine, Research & Experimental
Research & Experimental Medicine
Rhinovirus
Subunit vaccine
Antibodies
Epitope
Neutralisation
NEUTRALIZING ANTIBODY
MONOCLONAL-ANTIBODIES
NUMBERING SYSTEM
CAPSID PROTEIN
VACCINE
INFECTION
CELLS
RECEPTOR
PEPTIDE
VIRUS
Antibodies
Epitope
Neutralisation
Rhinovirus
Subunit vaccine
Science & Technology
Life Sciences & Biomedicine
Immunology
Medicine, Research & Experimental
Research & Experimental Medicine
Rhinovirus
Subunit vaccine
Antibodies
Epitope
Neutralisation
NEUTRALIZING ANTIBODY
MONOCLONAL-ANTIBODIES
NUMBERING SYSTEM
CAPSID PROTEIN
VACCINE
INFECTION
CELLS
RECEPTOR
PEPTIDE
VIRUS
06 Biological Sciences
07 Agricultural and Veterinary Sciences
11 Medical and Health Sciences
Virology
Publication Status: Published
Embargo Date: 2020-04-16
Online Publication Date: 2019-04-16
Appears in Collections:National Heart and Lung Institute
Airway Disease
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons